: Implementing risk management and real-time monitoring to ensure consistent quality throughout the product lifecycle. Key Stages in the A-Mab Bioprocess Development 1. Defining Critical Quality Attributes (CQAs)

Humanized IgG1 mAb targeting a cancer antigen. Indication: Solid tumors. Target Dose: 500 mg per patient, every 3 weeks. Annual Demand: 50 kg (clinical → early commercial). Critical Quality Attributes (CQAs):

A key output is the definition of a "design space"—the multidimensional combination of input variables (e.g., temperature, pH, feed rates) and process parameters that have been demonstrated to provide assurance of quality. Bioprocess Development Phases in A-Mab

The platform approach (CHO + Protein A + CEX/AEX + VF) reduced development time to from clone to phase 1 material.

At 10,000L scale, producing 100 kg/year of A Mab cost:

: Unlike theoretical guidelines, it provides a step-by-step walk-through of the development lifecycle, from target product profile to regulatory filing.

The purification process was scaled up from a 10 mL to a 100 L scale, demonstrating excellent scalability.